Serial TFT results post-diagnosis and following steroid and levothyroxine dose adjustment
| Date | TSH (mU/L; normal reference range 0.27–4.20) | T3 (pmol/L; normal reference range 3.1–6.8) | T4 (pmol/L; normal reference range 12.0–22.0) |
|---|---|---|---|
| 30/08/22 | 6.6 | 3.6 | 13.4 |
| 24/10/22 | 3.6 | 2.9 | 14.8 |
| 02/11/22 | 1.4 | 3.7 | 11.5 |
| 12/12/22 | 3.2 | 3.9 | 15.4 |
GP: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. AM: Conceptualization, Investigation, Writing—review & editing, Supervision. AOB and JS: Conceptualization, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
The authors confirm that the ethical approval for the publication of this case report has been exempted by the “The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool” in accordance with/based on/according to the ethics committee policy of the Trust. The research of this article meets the requirements of the Declaration of Helsinki.
Informed consent to participate in the study was obtained from all participants.
Informed consent to publication was obtained from relevant participants.
Not applicable.
Not applicable.
© The Author(s) 2024.